Document is current
Any future updates will be listed below
-
Authors
Kawamoto, Yasuharu https://orcid.org/0009-0009-1266-6313
Ikezawa, Kenji https://orcid.org/0000-0001-7517-8960
Tabuchi, Takahiro
Morishima, Toshitaka
Seiki, Yusuke
Watsuji, Ko
Hirao, Takeru
Higashi, Sena
Urabe, Makiko
Kai, Yugo
Takada, Ryoji
Yamai, Takuo
Mukai, Kaori
Nakabori, Tasuku
Uehara, Hiroyuki
Miyashiro, Isao
Ohkawa, Kazuyoshi
-
Funding
Funding for this research was provided by:
Japan Society for the Promotion of Science (21H04856, 21K10388)
Ministry of Health, Labour and Welfare (H30-Gantaisaku-Ippan-009)
- License Information
-
More Information
Article History
Received: 12 May 2023
Accepted: 2 June 2023
First Online: 18 July 2023
Declarations
:
: Kenji Ikezawa has received honoraria for lectures from Taiho Pharmaceutical, Yakult Honsha, Ono Pharmaceutical, MSD, Myriad Genetics, Asahi Kasei Pharma, and Incyte Biosciences Japan, as well as research funding from ASKA Pharmaceutical. Ryoji Takada has received honoraria for lectures from Hisamitsu Pharmaceutical, Novartis, and Teijin Pharma. Takuo Yamai has received honoraria for lectures from Taiho Pharmaceutical and Yakult Honsha. Kazuyoshi Ohkawa has received honoraria for lectures from Eisai, Chugai Pharmaceutical, Yakult Honsha, Incyte Biosciences Japan, Takeda, Gilead, and Hisamitsu, as well as research grants from Towa Pharmaceutical and Sumitomo Chemical. The other authors have no relevant financial or non-financial interests to disclose.
: This study was approved by the Institutional Review Board of the Osaka International Cancer Institute (approval number: 21077–3) and was designed and executed in accordance with the ethical standards of the 1964 Declaration of Helsinki and its later amendments. The study was registered under the registration number 21077–3.
: Because anonymized data from the OCR database were obtained in accordance with the Cancer Registry Promotion Act, informed consent was waived.
: Not applicable.
